Orakl Closes 30 Million Euro Series A for Tumor Models

Company Orakl Oncology Event Type Series A financing (€30 million) Modality Patient-derived tumor models and AI prediction platform Asset Predictive research platform Target Not applicable Disease Area Colorectal, pancreatic, lung and gastric cancer Summary Orakl Oncology’s co-lead investor Norrsken announced a new €30 million ($34…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *